Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study

Details

Serval ID
serval:BIB_974C42B1039A
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study
Journal
Journal of Neural Transmission
Author(s)
Onofrj  M., Thomas  A., Vingerhoets  F., Martin  W., Gimenez-Roldan  S., Azulay  J. P., Bernhard  G., Schmidt  W., Markabi  S.
ISSN
0300-9564 (Print)
Publication state
Published
Issued date
08/2004
Volume
111
Number
8
Pages
1053-63
Notes
Journal Article
Multicenter Study --- Old month value: Aug
Abstract
The efficacy of entacapone and its impact on patient quality of life (QOL) was investigated in an open-label study of 899 patients with idiopathic Parkinson's Disease (PD) experiencing wearing-off fluctuations. Patients were divided into 3 groups (3, 4 or 5 doses daily) based on their current levodopa dosage frequency. Patients received 200 mg entacapone with each levodopa/dopa-decarboxylase inhibitor (DDCI) dose, while continuing their same levodopa/DDCI dosage regimen for 4 weeks. Primary efficacy measure was the Investigators' Clinical Global Impression of Change (CGIC). Patient QoL was assessed using the validated 8-item Parkinson's Disease Questionnaire (PDQ-8). Investigators' CGIC revealed that 76.5% of entacapone treated patients experienced an improvement in global status after 4 weeks. Treatment with entacapone was also associated with improvement in patient QoL, with a mean reduction (improvement) in PDQ-8 score of 1.8 from baseline. This study confirms and extends the results of earlier studies demonstrating that, independent of dosing frequency, completing levodopa/DDCI therapy with entacapone provides clinically relevant improvements in global status and QoL in PD patients experiencing wearing-off on their current levodopa dosing frequency.
Keywords
Aged Antiparkinson Agents/administration & dosage/adverse effects/*therapeutic use Catechols/administration & dosage/adverse effects/*therapeutic use Disability Evaluation Dopa Decarboxylase/*antagonists & inhibitors Drug Therapy, Combination Enzyme Inhibitors/adverse effects/*therapeutic use Female Humans Levodopa/administration & dosage/adverse effects/*therapeutic use Male Middle Aged Parkinson Disease/*drug therapy/*psychology Quality of Life Questionnaires
Pubmed
Web of science
Create date
25/01/2008 12:49
Last modification date
20/08/2019 14:59
Usage data